Biggest change to treatment of RA since the introduction of biologics in the early 2000s
Biggest change to treatment of RA since the introduction of biologics in the early 2000s
11 June 2021

This article was original published on 11th June 2021 on www.hah.co.uk Sciensus is the new name for Healthcare at Home.

We are delighted to share the news, from one of our main charity partners, The National Rheumatoid Arthritis Society NRAS, that the National Institute for Health and Care Excellence (NICE) has issued draft guidance approving certain anti-TNF therapies to be prescribed for people with so-called ‘moderate’ rheumatoid arthritis.  The outcome of NRAS’ campaigning over the last four years is a huge step forward in providing equity of access to effective treatments for the many thousands of people who live with disease. It  will also provide patients with the opportunity to get treated quicker in their disease progression.   For more information, please visit the NRAS website.

Our Christmas and New Year opening times
How cutting-edge gassing isolators help Sciensus to treat cancer patients at home
Sciensus Rare: A key partner at World Orphan Drug Congress 2021
Sciensus shortlisted for second HR award of the year
Sciensus Shortlisted in the Investors in People Awards 2021
Hosting our latest ‘HSJ round table’: Can empowering patients help the NHS recover from Covid 19?